GRIA1 and schizophrenia: A2ARs increase the expression of the calcium-permeable GluA1 subunit of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropinonic acid (AMPA) receptor through the activation of protein kinase A [72], which, in part, explains the excitatory neuromodulatory effect associated with positive symptoms in schizophrenia and the potential antipsychotic benefit of A2AR antagonists.